Valuation : Aquestive Therapeutics, Inc.

Market Cap 641M 552M 518M 473M 889M 61.03B 895M 6.14B 2.39B 30.96B 2.41B 2.36B 102B P/E 2026 *
-10x
P/E 2027 * -10.6x
Enterprise Value 563M 485M 455M 416M 781M 53.61B 786M 5.39B 2.1B 27.19B 2.12B 2.07B 89.99B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.46x
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week+6.46%
Current month+38.29%
1 month+38.29%
3 months+27.75%
6 months+24.03%
Current year-20.90%
1 week 4.72
Extreme 4.72
5.41
1 month 3.65
Extreme 3.65
5.41
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 16/05/2022
Director of Finance/CFO 67 30/12/2020
Compliance Officer - 01/04/2026
Director TitleAgeSince
Chairman 72 31/03/2024
Director/Board Member 60 31/12/2003
Director/Board Member 50 16/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

Chief Executive Officer

-25,000 0.0199%
14/08/26 Tax

Executive/Senior Manager

-2,714 0.0022%
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%+6.46%+33.42%+211.59% 630M
-1.52%-7.86%+57.90%+111.09% 1,047B
-0.82%-1.62%+50.05%+62.37% 646B
+0.37%-3.22%+21.87%+72.88% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -0.10%-1.64%+28.15%+64.79% 365.99B
Weighted average by Cap. -0.01%-3.46%+36.91%+64.91%

Financials

2026 *2027 *
Net sales 49.93M 42.98M 40.35M 36.85M 69.17M 4.75B 69.68M 478M 186M 2.41B 187M 183M 7.98B 67.77M 58.34M 54.77M 50.02M 93.89M 6.45B 94.58M 649M 252M 3.27B 254M 249M 10.83B
Net income -63.62M -54.77M -51.42M -46.95M -88.14M -6.05B -88.79M -609M -237M -3.07B -239M -234M -10.16B -60.23M -51.85M -48.68M -44.45M -83.44M -5.73B -84.06M -576M -224M -2.91B -226M -221M -9.62B
Net Debt -78M -67.15M -63.04M -57.57M -108M -7.42B -109M -747M -290M -3.76B -293M -286M -12.46B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
31/08/26 US$5.100 +1.59% 1,907,006
28/08/26 US$5.020 -2.71% 2,517,467
27/08/26 US$5.160 -4.27% 3,663,314
26/08/26 US$5.390 +6.10% 3,412,030
25/08/26 US$5.080 +5.83% 3,668,722
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.100USD
Average target price
9.333USD
Spread / Average Target
+83.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock